Obu Health review

What it is

OBU Health LLC is a Las Vegas telehealth platform at 10845 Griffith Peak Dr, running a compact four-product catalogue: sermorelin from $149, NAD+ Injection at $219, compounded semaglutide from $190/mo and compounded tirzepatide from $239/mo. It advertises US board-certified physician review within about 24 hours, free expedited shipping, discreet packaging and a stated four-test pharmacy quality panel, and it publishes a LegitScript seal with a verification ID on its homepage.

How it works

Asynchronous and questionnaire-based: a short health assessment, licensed physician review, and delivery from one of two named partner pharmacies. Two features stand out. The first is supply-chain transparency — naming Manifest Pharmacy and RX Compounding Store puts Obu ahead of essentially every competitor on this board, because it means you can look up who prepares your medication rather than accepting 'a licensed US pharmacy' as an answer. The second is that its product pages state what the price covers: the provider consultation, ongoing care and dose adjustments are all listed as included, with free expedited shipping and pause-or-cancel-anytime terms, and its sermorelin plan explicitly promises the same price per vial on the monthly plan and the same price at every refill on the three-month plan. The gaps: no medical director is named publicly, no enumerated state list exists (the FAQ says the US only, with restrictions depending on therapy and state), and the refund position is firm — federal and state law do not allow medication returns, so all sales are final. Subscription auto-renewal mechanics are only lightly documented, so read them at checkout.

Pricing transparency

Sermorelin is $149 per month on the monthly plan or $379 for three months, and the NAD⁺ injection is $219 per month, each with the provider visit, dose adjustments, ongoing care and free expedited shipping stated as included. Obu's own comparison table puts a $149 starting price against several named competitors, which is marketing framing rather than our assessment, and its 'From' pricing on the GLP-1 side ($190/mo semaglutide, $239/mo tirzepatide) is a starting figure with per-dose tiers not published — a limitation that may apply to the peptide line too, so confirm whether $149 holds at higher doses. Subscription tiers of one, three, six and twelve months are shown on the site with per-tier pricing not fully displayed. None of the GLP-1 figures is a peptide or NAD⁺ price and we have not carried them across.

Branded vs compounded

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Obu states this in its own FAQ — compounded sermorelin is not FDA-approved, is prepared by a US-licensed pharmacy under Section 503A, and is dispensed only against a patient-specific prescription, with the FDA not reviewing or approving compounded medications for safety, effectiveness or quality. That is an unusually precise disclosure, and it is backed by naming the two pharmacies. Compounded sterile preparations are still not reviewed by the FDA for purity and potency the way approved drugs are. On evidence, sermorelin is a GHRH analogue that signals your own pituitary to release growth hormone rather than replacing it, which preserves the natural feedback loop — a real, well-described mechanism whose long-term human outcome data behind sleep, recovery and body-composition claims stays thin. Obu's own FAQ makes the sermorelin-versus-HGH distinction correctly. Injected NAD⁺ is weaker: no controlled human outcome trials exist for it, and the NAD⁺ forms with human data are the oral precursors NR and NMN, which raise blood NAD⁺ — a biomarker, not a clinical outcome. Individual results vary.

Pros and watch-outs

The evidence behind what Obu Health prescribes

We grade the molecules, not the marketing. Here is what the human data actually shows for each thing on their menu.

• Sermorelin: a real GHRH drug, read against the anti-aging pitch

  An approved growth-hormone-releasing analog with a pediatric track record — and a longevity case built more on biomarkers than outcomes.

• NAD+ precursors (NR and NMN): what the human trials actually show

  They raise NAD+ and look safe short-term — but human evidence is surrogate-marker level, and no trial shows they extend healthspan.

How Obu Health compares

A few alternatives worth a look, depending on what you’re optimizing for.

• NMNova MD

  NAD⁺ buyers who want the concentration and vial size stated, not just a monthly fee

  See Nova MD →
• NSNeo Soma Healthcare

  Reading an NAD⁺ price on a storefront rather than being quoted one after intake

  See Neo Soma Healthcare →
• OWOnyx Weight Loss

  NAD⁺ from a named clinical team and a named pharmacy, if you live in one of its eight states

  See Onyx Weight Loss →